Janux Therapeutics (JANX) Total Liabilities (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Total Liabilities of $86.7 million for Q1 2026, up 126.33% year-over-year from $38.3 million in Q1 2025, and up 93.75% quarter-over-quarter from $44.7 million in Q4 2025.
Janux Therapeutics (JANX) Total Liabilities (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Total Liabilities for 7 consecutive years, with $86.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 126.33% year-over-year to $86.7 million; the TTM figure through Mar 2026 stood at $86.7 million (up 126.33% YoY), while the FY2025 annual figure was $44.7 million, up 15.51% from the prior year.
- Total Liabilities improved to $86.7 million in Q1 2026 per JANX's latest filing, from $44.7 million in the prior quarter.
- Across five years, Total Liabilities topped out at $86.7 million in Q1 2026 and bottomed at $12.5 million in Q1 2022.
- Historically, Total Liabilities has averaged $41.4 million across 5 years, with a median of $41.6 million in 2022.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 245.45% — and 2024, when it fell 20.32%.
- Janux Therapeutics' Total Liabilities stood at $43.3 million in 2022, then fell by 16.67% to $36.1 million in 2023, then grew by 7.42% to $38.7 million in 2024, then increased by 15.51% to $44.7 million in 2025, then surged by 93.75% to $86.7 million in 2026.
- Business Quant data shows JANX's Total Liabilities at $86.7 million in Q1 2026, $44.7 million in Q4 2025, and $48.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 79.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.67 Mn |
| Mar 31, 2026 | 86.69 Mn |
| Dec 31, 2025 | 44.74 Mn |
| Sep 30, 2025 | 48.21 Mn |
| Jun 30, 2025 | 41.70 Mn |
| Mar 31, 2025 | 38.30 Mn |
| Dec 31, 2024 | 38.74 Mn |
| Sep 30, 2024 | 38.92 Mn |
| Jun 30, 2024 | 33.74 Mn |
| Mar 31, 2024 | 33.22 Mn |
| Dec 31, 2023 | 36.06 Mn |
| Sep 30, 2023 | 37.90 Mn |
| Jun 30, 2023 | 42.03 Mn |
| Mar 31, 2023 | 41.69 Mn |
| Dec 31, 2022 | 43.27 Mn |
| Sep 30, 2022 | 44.24 Mn |
| Jun 30, 2022 | 41.55 Mn |
| Mar 31, 2022 | 12.52 Mn |
| Dec 31, 2021 | 13.50 Mn |
| Sep 30, 2021 | 14.33 Mn |